Year: 2026
Type: article
Abstract: The pharmaceutical industry faces a persistent crisis of productivity: drug development remains prohibitively expensive, time-consuming, and failure-prone. Artificial Intelligence (AI) is emerging as a transformative force capable of revolutionizing every stage of the drug discovery pipeline from multi-omics-driven target identification and generative molecular design to adaptive clinical trial management and regulatory review. This review paper examines the current landscape of AI applications in drug discovery, including machine learning (ML) techniques, deep learning architectures, natural language processing (NLP), and large language models (LLMs). We analyze real-world case studies, compare AI-driven workflows with conventional methodologies, discuss challenges such as data quality, algorithmic bias, and regulatory uncertainty, and propose a framework for responsible AI integration in pharmaceutical R&D. The paper further explores future directions including quantum AI, digital twin simulations, and federated learning. Our analysis concludes that while significant barriers remain, AI presents an unprecedented opportunity to accelerate life-saving treatments and fundamentally reshape drug development economics.
Authors: Drishith Kapoor, Raghu Raja Mehra
Language: English
Subfield: Drug Discovery
Domain: Life Sciences
Open Access status: diamond
OpenAlex ID: W7156155128
